$NUVL News

Bernstein Downgrades Nuvalent to Market Perform, Lowers Price Target to $124

TD Cowen Downgrades Nuvalent to Hold, Announces $124 Price Target

Barclays Downgrades Nuvalent to Equal-Weight, Lowers Price Target to $124

Wedbush Downgrades Nuvalent to Neutral, Lowers Price Target to $124

UBS Downgrades Nuvalent to Neutral, Lowers Price Target to $124

Guggenheim Downgrades Nuvalent to Neutral, Lowers Price Target to $124

Wells Fargo Downgrades Nuvalent to Equal-Weight, Raises Price Target to $124

LifeSci Capital Downgrades Nuvalent to Market Perform, Announces $124 Price Target

HC Wainwright & Co. Downgrades Nuvalent to Neutral, Announces $124 Price Target

Cantor Fitzgerald Downgrades Nuvalent to Neutral

Wedbush Downgrades Nuvalent to Neutral, Lowers Price Target to $124

Wedbush Reiterates Outperform on Nuvalent, Maintains $125 Price Target

Nuvalent Announces Acceptance Of Its NDA For Neladalkib For Filing By FDA, With PDUFA Target Action Date Of November 27

Bernstein Initiates Coverage On Nuvalent with Outperform Rating, Announces Price Target of $189

Nuvalent To Present Pivotal ALKOVE-1 Data For Neladalkib In TKI-Pretreated ALK-Positive NSCLC And Early ARROS-1 Results For Zidesamtinib In ROS1-Positive Solid Tumors At ASCO 2026

Nuvalent Inc-A (NASDAQ:NUVL) Stock Edges Higher After Q1 2026 Earnings Miss as Investors Focus on Pipeline Milestones

Nuvalent Q1 EPS $(1.39) Misses $(1.36) Estimate

Nuvalent (NUVL) Submits NDA to FDA for Neladalkib in ALK-Positive NSCLC

Nuvalent: A Precision Oncology Platform With Two Near-Term Shots On Goal

Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform